Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablati...
Saved in:
| Published in | BMC medicine Vol. 22; no. 1; pp. 605 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
31.12.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia.
We performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m
/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m
/day on days -10 to -6; the same dose of TBI-Cy).
Between April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups.
These results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. |
|---|---|
| AbstractList | Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia. Methods We performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m.sup.2/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m.sup.2/day on days -10 to -6; the same dose of TBI-Cy). Results Between April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups. Conclusions These results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. Keywords: Decitabine, Intensified conditioning, Allo-HSCT, KMT2A-r leukemia Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia. We performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m /day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m /day on days -10 to -6; the same dose of TBI-Cy). Between April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups. These results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. Abstract Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia. Methods We performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m2/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m2/day on days -10 to -6; the same dose of TBI-Cy). Results Between April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups. Conclusions These results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia.BACKGROUNDAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia.We performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m2/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m2/day on days -10 to -6; the same dose of TBI-Cy).METHODSWe performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m2/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m2/day on days -10 to -6; the same dose of TBI-Cy).Between April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups.RESULTSBetween April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups.These results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT.CONCLUSIONSThese results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. BackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia.MethodsWe performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m2/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m2/day on days -10 to -6; the same dose of TBI-Cy).ResultsBetween April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups.ConclusionsThese results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains high. We aimed to determine whether intensified conditioning containing decitabine (Dec) could reduce relapse compared with standard myeloablative conditioning in adult patients with KMT2A-r leukemia. We performed a multicenter retrospective study at seven institutions in China. Eligible patients were aged 14 years or older at transplantation, had a diagnosis of KMT2A-r leukemia, and underwent the first allo-HSCT. Standard myeloablative conditioning regimens (standard group) included BuCy (busulfan 3.2 mg/kg/day on days -7 to -4; cyclophosphamide 60 mg/kg/day on days -3 to -2) and TBI-Cy (total body irradiation 4.5 Gy/day on days -5 to -4; Cy 60 mg/kg/day on days -3 to -2). Intensified conditioning regimens containing Dec (intensified group) consisted of Dec-BuCy (Dec 20 mg/m.sup.2/day on days -14 to -10; the same dose of BuCy) and Dec-TBI-Cy (Dec 20 mg/m.sup.2/day on days -10 to -6; the same dose of TBI-Cy). Between April 2009 and December 2019, 218 patients were included in this study, of whom 105 were in the intensified group and 113 were in the standard group. The 3-year cumulative incidence of relapse was 17.6% and 34.5%, overall survival was 71.3% and 61.0%, disease-free survival was 70.1% and 56.0%, and non-relapse mortality was 12.3% and 9.5% in the intensified and standard groups, respectively (P = 0.001; P = 0.034; P = 0.005; P = 0.629). Subgroup analysis showed that the relapse rate of intensified conditioning was lower than that of standard conditioning in multiple subgroups, including different leukemia types, disease status at transplantation, high-risk cytogenetics and Bu-based regimens. There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups. These results suggest that intensified conditioning containing Dec might be a better strategy than standard myeloablative conditioning for adult patients with KMT2A-r leukemia undergoing allo-HSCT. |
| ArticleNumber | 605 |
| Audience | Academic |
| Author | Huang, Fen Li, Yiqing Zeng, Yunxin Jin, Hua He, Hai Xu, Na Sun, Ruijuan Zhu, Ping Liu, Can Lin, Ren Fan, Zhiping Hu, Zhongli Dong, Ying Xuan, Li Feng, Zinan Liu, Shiqi Liu, Qifa Zhang, Xiong |
| Author_xml | – sequence: 1 givenname: Zhongli surname: Hu fullname: Hu, Zhongli – sequence: 2 givenname: Zinan surname: Feng fullname: Feng, Zinan – sequence: 3 givenname: Shiqi surname: Liu fullname: Liu, Shiqi – sequence: 4 givenname: Hai surname: He fullname: He, Hai – sequence: 5 givenname: Ying surname: Dong fullname: Dong, Ying – sequence: 6 givenname: Zhiping surname: Fan fullname: Fan, Zhiping – sequence: 7 givenname: Yiqing surname: Li fullname: Li, Yiqing – sequence: 8 givenname: Fen surname: Huang fullname: Huang, Fen – sequence: 9 givenname: Na surname: Xu fullname: Xu, Na – sequence: 10 givenname: Can surname: Liu fullname: Liu, Can – sequence: 11 givenname: Yunxin surname: Zeng fullname: Zeng, Yunxin – sequence: 12 givenname: Ping surname: Zhu fullname: Zhu, Ping – sequence: 13 givenname: Ren surname: Lin fullname: Lin, Ren – sequence: 14 givenname: Hua surname: Jin fullname: Jin, Hua – sequence: 15 givenname: Xiong surname: Zhang fullname: Zhang, Xiong – sequence: 16 givenname: Ruijuan surname: Sun fullname: Sun, Ruijuan – sequence: 17 givenname: Qifa surname: Liu fullname: Liu, Qifa – sequence: 18 givenname: Li surname: Xuan fullname: Xuan, Li |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39736728$$D View this record in MEDLINE/PubMed |
| BookMark | eNptktuO0zAQhiO0iD3AC3CBIiEhbrLYjuO43KyqFYeKRdws19bEnrReUrvYTlFfimfEbZeqRciSj5__8Yz_y-LMeYdF8ZKSa0qleBcpm1BREcYrUsuaVORJcUFbTquW0ObsaH5eXMb4QAhr2pY_K87rSVuLlsmL4vfMJXTR9hZNqb0zNlnvrJtvFwnsbmpQ2wSddViuMcQxljGBMxBMudzg4KEbINk1ngr0PpRgxiGVq3yKLsXyl02L8svXezatAkII4OY57IDjD1xaeF9Cucy81RnGUAZMwccV6p12TKPZPC-e9jBEfPE4XhXfP364v_1c3X37NLud3lW64SJVvGOCcQAKnQEjmO641BSNyQOjWmvTsRo6IppGcylBT0zTMEmE7JFAjfVVMdvrGg8PahXsEsJGebBqt-HDXEHIDx1Q9R0VGlrR5ECckaYjugOY1FLnUIKyrHWz11qN3RLNNrkAw4no6YmzCzX3a0WpkC3hIiu8fVQI_ueIMamljRqHARz6MaqaNqTmOQGe0df_oA9-DC7XaksxMWl5Zg_UHHIG1vU-B9ZbUTWVjErZTGSdqev_ULmZ_Fv5q7G3ef_kwpujCwuEIS2iH8atI-Ip-Oq4JIda_PVlBtge0NkBMWB_QChRW_OrvflVNr_amT_3fwDCE_rB |
| Cites_doi | 10.1038/s41408-021-00557-6 10.1016/j.canlet.2024.217264 10.1182/blood.2022017645 10.6004/jnccn.2023.0025 10.1016/j.bbmt.2014.12.001 10.1200/JCO.2008.16.7981 10.1038/s41375-021-01218-0 10.1038/s41375-021-01135-2 10.1002/sim.7501 10.3389/fonc.2022.844937 10.1038/s41409-021-01238-5 10.6004/jnccn.2021.0042 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O 10.1038/s41375-023-01877-1 10.1200/JCO.1988.6.10.1562 10.1016/j.bbmt.2018.07.021 10.6004/jnccn.2020.0021 10.1016/j.exphem.2018.08.002 10.1200/JCO.22.01297 10.1200/JCO.19.03011 10.1016/S2352-3026(23)00117-5 10.1002/(SICI)1096-8652(199806)58:2<130::AID-AJH8>3.0.CO;2-T 10.12659/MSM.899186 10.1038/leu.2015.143 10.1038/s41409-020-0803-y 10.1186/s13045-020-00859-5 10.1158/1078-0432.CCR-06-2762 10.1038/s41591-022-01720-7 10.2147/CMAR.S229768 10.1038/s41586-023-05812-3 10.1126/scitranslmed.abc4834 10.1016/S2352-3026(22)00375-1 10.1186/s13045-021-01159-2 10.1182/blood-2009-04-215152 10.1200/JCO.22.02120 10.1186/s13045-021-01057-7 10.1016/j.blre.2016.08.005 10.1038/s43018-022-00366-1 10.1056/NEJMoa2004444 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12916-024-03830-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_fb16ca765ad64205b0cbaa938cc21612 PMC11687046 A821885983 39736728 10_1186_s12916_024_03830_0 |
| Genre | Multicenter Study Comparative Study Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 82293634 – fundername: National Key Research and Development Program of China grantid: 2021YFC2500300-4 – fundername: National Key Research and Development Program of China grantid: 2022YFC2502600-5 – fundername: Natural Science Foundation of Guangdong Province grantid: 2024A1515010794 – fundername: National Natural Science Foundation of China grantid: 82170213 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PUEGO PMFND 3V. 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c546t-4b2624aa1abdad62cb48c1edd48c21cccdb23ab0655c488ac9d5528068fe0a3e3 |
| IEDL.DBID | M48 |
| ISSN | 1741-7015 |
| IngestDate | Wed Aug 27 01:18:58 EDT 2025 Thu Aug 21 18:35:44 EDT 2025 Fri Jul 11 10:58:26 EDT 2025 Fri Jul 25 21:48:41 EDT 2025 Tue Jun 17 21:59:12 EDT 2025 Tue Jun 10 20:58:39 EDT 2025 Thu May 22 21:23:36 EDT 2025 Thu Aug 28 04:45:46 EDT 2025 Tue Jul 01 02:51:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Decitabine Intensified conditioning Allo-HSCT KMT2A-r leukemia |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c546t-4b2624aa1abdad62cb48c1edd48c21cccdb23ab0655c488ac9d5528068fe0a3e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3152697450?pq-origsite=%requestingapplication% |
| PMID | 39736728 |
| PQID | 3152697450 |
| PQPubID | 42775 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fb16ca765ad64205b0cbaa938cc21612 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11687046 proquest_miscellaneous_3150345284 proquest_journals_3152697450 gale_infotracmisc_A821885983 gale_infotracacademiconefile_A821885983 gale_healthsolutions_A821885983 pubmed_primary_39736728 crossref_primary_10_1186_s12916_024_03830_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-31 |
| PublicationDateYYYYMMDD | 2024-12-31 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medicine |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Krauter (3830_CR42) 2009; 27 X Tang (3830_CR16) 2021; 56 GC Issa (3830_CR6) 2021; 11 A Spyridonidis (3830_CR15) 2020; 55 L Xuan (3830_CR23) 2023; 10 DA Pollyea (3830_CR27) 2023; 21 R Zhang (3830_CR40) 2019; 25 BC Valdez (3830_CR37) 2018; 67 3830_CR24 C Meyer (3830_CR29) 2023; 37 HZ Qi (3830_CR11) 2021; 11 PC Austin (3830_CR34) 2017; 36 PA Brown (3830_CR28) 2021; 19 I Iacobucci (3830_CR8) 2022; 140 QY Wang (3830_CR22) 2019; 11 Y Wang (3830_CR10) 2014; 89 S Yu (3830_CR17) 2020; 13 H Zhang (3830_CR25) 2023; 41 BJ Aubrey (3830_CR7) 2022; 3 E Khabirova (3830_CR2) 2022; 28 AH Wei (3830_CR39) 2020; 383 GC Issa (3830_CR1) 2023; 615 3830_CR12 XH Zhang (3830_CR18) 2021; 14 3830_CR30 A Attarbaschi (3830_CR4) 2023; 41 3830_CR31 Y Wang (3830_CR19) 2024; 2024 L Xuan (3830_CR26) 2023; 10 BV Balgobind (3830_CR41) 2009; 114 TA Gooley (3830_CR33) 1999; 18 X Li (3830_CR5) 2021; 14 SI Bearman (3830_CR32) 1988; 6 H Yang (3830_CR9) 2016; 22 T Qin (3830_CR38) 2007; 13 RE van Weelderen (3830_CR3) 2023; 41 CS Hourigan (3830_CR14) 2020; 38 J Prada-Arismendy (3830_CR36) 2017; 31 J Stomper (3830_CR20) 2021; 35 Z Li (3830_CR21) 2022; 12 A Touzart (3830_CR35) 2021; 13 A Pigneux (3830_CR13) 2015; 29 |
| References_xml | – volume: 11 start-page: 162 issue: 9 year: 2021 ident: 3830_CR6 publication-title: Blood Cancer J doi: 10.1038/s41408-021-00557-6 – volume: 11 start-page: 1683 issue: 4 year: 2021 ident: 3830_CR11 publication-title: Am J Cancer Res – volume: 2024 start-page: 217264 year: 2024 ident: 3830_CR19 publication-title: Cancer Lett doi: 10.1016/j.canlet.2024.217264 – volume: 140 start-page: 1833 issue: 17 year: 2022 ident: 3830_CR8 publication-title: Blood doi: 10.1182/blood.2022017645 – volume: 21 start-page: 503 issue: 5 year: 2023 ident: 3830_CR27 publication-title: J Natl Compr Canc Netw. doi: 10.6004/jnccn.2023.0025 – ident: 3830_CR31 doi: 10.1016/j.bbmt.2014.12.001 – volume: 41 start-page: 343 issue: 2 year: 2023 ident: 3830_CR25 publication-title: Phase III Trial J Clin Oncol – volume: 27 start-page: 3000 issue: 18 year: 2009 ident: 3830_CR42 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.7981 – volume: 35 start-page: 1873 issue: 7 year: 2021 ident: 3830_CR20 publication-title: Leukemia doi: 10.1038/s41375-021-01218-0 – ident: 3830_CR12 doi: 10.1038/s41375-021-01135-2 – volume: 36 start-page: 4391 issue: 27 year: 2017 ident: 3830_CR34 publication-title: Stat Med doi: 10.1002/sim.7501 – volume: 12 start-page: 844937 year: 2022 ident: 3830_CR21 publication-title: Front Oncol doi: 10.3389/fonc.2022.844937 – volume: 56 start-page: 1674 issue: 7 year: 2021 ident: 3830_CR16 publication-title: Bone Marrow Transplant doi: 10.1038/s41409-021-01238-5 – volume: 19 start-page: 1079 issue: 9 year: 2021 ident: 3830_CR28 publication-title: J Natl Compr Canc Netw. doi: 10.6004/jnccn.2021.0042 – volume: 18 start-page: 695 issue: 6 year: 1999 ident: 3830_CR33 publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O – volume: 37 start-page: 988 issue: 5 year: 2023 ident: 3830_CR29 publication-title: Leukemia doi: 10.1038/s41375-023-01877-1 – volume: 6 start-page: 1562 issue: 10 year: 1988 ident: 3830_CR32 publication-title: J Clin Oncol doi: 10.1200/JCO.1988.6.10.1562 – volume: 25 start-page: 47 issue: 1 year: 2019 ident: 3830_CR40 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2018.07.021 – ident: 3830_CR24 doi: 10.6004/jnccn.2020.0021 – ident: 3830_CR30 – volume: 67 start-page: 49 year: 2018 ident: 3830_CR37 publication-title: Exp Hematol doi: 10.1016/j.exphem.2018.08.002 – volume: 41 start-page: 1404 issue: 7 year: 2023 ident: 3830_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.22.01297 – volume: 38 start-page: 1273 issue: 12 year: 2020 ident: 3830_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.19.03011 – volume: 10 start-page: e600 issue: 8 year: 2023 ident: 3830_CR26 publication-title: Lancet Haematol doi: 10.1016/S2352-3026(23)00117-5 – volume: 89 start-page: 130 issue: 2 year: 2014 ident: 3830_CR10 publication-title: Am J Hematol doi: 10.1002/(SICI)1096-8652(199806)58:2<130::AID-AJH8>3.0.CO;2-T – volume: 22 start-page: 2315 year: 2016 ident: 3830_CR9 publication-title: Med Sci Monit doi: 10.12659/MSM.899186 – volume: 29 start-page: 2375 issue: 12 year: 2015 ident: 3830_CR13 publication-title: Leukemia doi: 10.1038/leu.2015.143 – volume: 55 start-page: 1114 issue: 6 year: 2020 ident: 3830_CR15 publication-title: Bone Marrow Transplant doi: 10.1038/s41409-020-0803-y – volume: 13 start-page: 18 issue: 1 year: 2020 ident: 3830_CR17 publication-title: J Hematol Oncol doi: 10.1186/s13045-020-00859-5 – volume: 13 start-page: 4225 issue: 14 year: 2007 ident: 3830_CR38 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2762 – volume: 28 start-page: 743 issue: 4 year: 2022 ident: 3830_CR2 publication-title: Nat Med doi: 10.1038/s41591-022-01720-7 – volume: 11 start-page: 10195 year: 2019 ident: 3830_CR22 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S229768 – volume: 615 start-page: 920 issue: 7954 year: 2023 ident: 3830_CR1 publication-title: Nature doi: 10.1038/s41586-023-05812-3 – volume: 13 start-page: eabc4834 issue: 595 year: 2021 ident: 3830_CR35 publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.abc4834 – volume: 10 start-page: e178 issue: 3 year: 2023 ident: 3830_CR23 publication-title: Lancet Haematol doi: 10.1016/S2352-3026(22)00375-1 – volume: 14 start-page: 145 issue: 1 year: 2021 ident: 3830_CR18 publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01159-2 – volume: 114 start-page: 2489 issue: 12 year: 2009 ident: 3830_CR41 publication-title: Blood doi: 10.1182/blood-2009-04-215152 – volume: 41 start-page: 2963 issue: 16 year: 2023 ident: 3830_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.22.02120 – volume: 14 start-page: 56 issue: 1 year: 2021 ident: 3830_CR5 publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01057-7 – volume: 31 start-page: 63 issue: 1 year: 2017 ident: 3830_CR36 publication-title: Blood Rev doi: 10.1016/j.blre.2016.08.005 – volume: 3 start-page: 595 issue: 5 year: 2022 ident: 3830_CR7 publication-title: Nat Cancer doi: 10.1038/s43018-022-00366-1 – volume: 383 start-page: 2526 issue: 26 year: 2020 ident: 3830_CR39 publication-title: N Engl J Med doi: 10.1056/NEJMoa2004444 |
| SSID | ssj0025774 |
| Score | 2.424157 |
| Snippet | Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse remains... Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse... BackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas relapse... Abstract Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with KMT2A-rearranged (KMT2A-r) leukemia whereas... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 605 |
| SubjectTerms | 5-aza-2'-deoxycytidine Acute leukemia Adolescent Adult Aged Allo-HSCT Allografts Blood Blood platelets Bone marrow Busulfan Cancer Care and treatment China - epidemiology Conditioning Cyclophosphamide Cytogenetics Decitabine Decitabine - administration & dosage Decitabine - therapeutic use Disease prevention Female Gene Rearrangement Graft versus host disease Graft-versus-host reaction Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Histone-Lysine N-Methyltransferase - genetics Humans Intensified conditioning Irradiation KMT2A-r leukemia Leukemia Leukemia - therapy Male Medical diagnosis Medical prognosis Middle Aged Myeloid-Lymphoid Leukemia Protein - genetics Neutrophils Patient outcomes Patients Relapse Remission (Medicine) Retrospective Studies Stem cell transplantation Stem cells Subgroups Survival Toxicity Transplantation Transplantation Conditioning - methods Transplantation, Homologous - methods Transplants & implants Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxJvAAkZC4oCitR3bcbgVxGoFKqddaW-WPXZFRTddpemBP8VvZOwkVSMOXDhVradV7Xl944w_E_JOaQeOcaxOGmVKGSCWjWtCCTzUgfEYed4aWH7XF1fy67W6PrrqK_WEDfTAw8KdrTzX4GqtXECozJRn4J1rKgMgEK3k6Is5byqmxlJLIaqZjsgYfbbDrMZTs60sGZZkrGSzNJTZ-v-OyUdJad4weZSBzh-Q-yN0pIvhLz8kd2L7iNxdjg_HH5PfYzv6ClElxTI3rMfN1vSmH26CoCHCundYDkeaGjL2OzptJtCbX3GzdX6TqcDnP4DIlmamDjrysO5o2sCl35aXYlF2qd83HVIIdBP3P-PN2n2kjuZexTSX2NEu9t12OtVJM6ftE3J1_uXy80U5XsdQgpK6L6UXWkjnuPMBlSHASwM8hoAvggNA8KJyHjGNAgwLDpqgVHpwa1aRuSpWT8lJu23jc0IlIE4ySgCWl7IBY3TQzgDjXsTaRFOQD5N27O3AumFztWK0HXRpUZc269KygnxKCjxIJsbs_AHakR3tyP7LjgryJqnfDsdPD35vFwZBkFGNqQryPkskz0crADceYMApJQ6tmeTpTBI9FubDk4nZMWLsbMXTXe-1VDidt4fh9M3UBdfG7T7LsErimsqCPBss8jBpxJWVrgUunZnZ6mxV5iPt-kfmE-dcY9SW-sX_WMeX5J5Ifpa5ME_JSd_t4yvEbb1_nV30Dx-2RSo priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2ggJGQOKCotmM7Dhe0IKoKtJxaaW-WXwsrtpuSzR76p_obGTvOthESp1XWk8j2PDwzHn9G6J2QxhlCITpphCq5d6FsTONLR33tCQ2BptTA_Ic8OePfFmKRE27bXFY52sRkqH3rYo78qKLxLuyaC_Lp4k8Zb42Ku6v5Co3b6E6ELotSXS-uAy4Bvs14UEbJoy2sbTSW3PKSQGBGSjJZjBJm_7-W-cbSNC2bvLEOHT9A97MDiWcDxx-iW2HzCN2d5y3yx-gqF6UvwbfEEOz6VU65xod-uA8C--BWvYGgOOBYlrHb4jGlgM8vw7o1dp0AwacfAP8WJ7wOnNFYtzimcfH3-SmblV2s-o1HFTxeh93vcL4yH7HBqWIxjiV0uAt9145nO3FCtn2Czo6_nn45KfOlDKUTXPYlt0wybgw11hsvmbNcORq8hx9GnXPesspY8GyEA-NgXOOFiNu3ahmIqUL1FB1s2k14jjB34C0pwRwEmbxxSkkvjXKEWhZqFVSBPozc0RcD9oZOMYuSeuClBl7qxEtNCvQ5MnBPGXGz0x9t91NnNdRLS6UztRTQdc6IsMRZY5pKOeg8OHsFehPZr4dDqHvt1zMFrpASjaoK9D5RRP0HKXAmH2OAIUUkrQnl4YQS9NZNm0cR09lubPW1lBfo7b45vhlr4Tah3SUaUnGYU16gZ4NE7gcN3mUlawZTpyayOpmVactm9SuhilMqwXZz-eL__XqJ7rGoQQnr8hAd9N0uvAK_rLevk_L9BYI1PGY priority: 102 providerName: ProQuest |
| Title | Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39736728 https://www.proquest.com/docview/3152697450 https://www.proquest.com/docview/3150345284 https://pubmed.ncbi.nlm.nih.gov/PMC11687046 https://doaj.org/article/fb16ca765ad64205b0cbaa938cc21612 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_nHYgv4rfVc40g-CDVJk3SVBDZlTsOZQ85bmHxJeRrdXFvq90ueP-Uf6OTtF2ueC--bNkmLU1mJjOTzPwGoZdcaKszAt5JyWXKnPVpqUuXWuIKlxHvSdwamJ6Kkxn7NOfzPdSXO-omcHOtaxfqSc3q1Zvfvy4_gMC_jwIvxdsN6CwSQmlZmoHDlaXgwh-AZipCRYMp250qAHdGVGYwwklagB7sk2iufcdAUUU8_39X7StqaxhSeUVHHd9BtzvjEo9bbriL9vz6Hro57Y7P76M_XcD6AuxODI6wW3bbseFP09aKwM7bZaPBYfY4hGxsN7jfbsAXl35VabOKYOHDF4DtiyOWB-6QWjc4bPHiz9NzOk7rEBEc0hgcXvntD3-x1O-wxjGaMYzF17j2TV31eZ84ot4-QLPjo_OPJ2lXsCG1nIkmZYYKyrQm2jjtBLWGSUu8c3ChxFrrDM21AauHW1g4tC0d5-FoVy58pnOfP0T762rtHyPMLFhSklMLDigrrZTCCS1tRgz1hfQyQa976qifLS6Hiv6MFKqlpQJaqkhLlSVoEgi46xkwteONqv6mOhFVC0OE1YXg8OmMZtxk1mhd5tLCx4MhmKDngfyqTVDdrQxqLMFMkryUeYJexR6BW4ELrO5SHGBIAWVr0PNw0BNk2g6bexZTvUionIRq8AXjMJwXu-bwZIiTW_tqG_tkOYM5ZQl61HLkbtBgeeaioDB1csCrg1kZtqyX3yPiOCEC1nUmnvzXrD9Ft2gQqAiLeYj2m3rrn4EJ15gRulHMixE6mBydfjkbxY2QUZRV-D2bfP0L8bZJpw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BpDAl4QdwKDGQnEA4pmO7bjICFULlNH1z110t6MY7tQ0TWjTYX2U_tGjp2kW4TE256ixqeR7XN8bj4XhF4LaawhFKyTQqiUO-vTwhQutdTljlDvaXQNjI_k8Jh_OxEnW-iiy4UJYZUdT4yM2lU2-Mj3Mhp6YedckI9nv9PQNSrcrnYtNBqyGPnzP2CyrT4cfAH8vmFs_-vk8zBtuwqkVnBZp7xkknFjqCmdcZLZkitLvXPwYNRa60qWmRJEs7BA3cYWTohw_6imnpjMZ_DdG-gmCF4SjL385NLAE6BLdYk5Su6tQJbSEOLLUwKGIElJT_jFHgH_SoIrorAfpnlF7u3fQ3dbhRUPGgq7j7b84gG6NW6v5B-iizYIfgq6LAbj2s1aF2_4UTf9J7DzdlYbMMI9DmEg6xXuXBj49NzPK1POYwHy_gdAn8axPghuq7-ucHAb49F4wgbpMkQZh9QIh-d-_cufzsx7bHCMkAxr8Uu89PWy6nJJcayk-wgdXwu6HqPtRbXwTxHmFrQzJZgFo5YXVinppFGW0JL5XHmVoHcddvRZU-tDRxtJSd3gUgMudcSlJgn6FBC4gQx1uuOLavlDt8deT0sqrcmlgKlzRkRJbGlMkSkLkwflMkG7Af26SXrdcBs9UKB6KVGoLEFvI0TgN0AF1rRpE7CkULmrB7nTgwQ-YfvDHYnplk-t9OWpStCrzXD4Z4i9W_hqHWFIxmFPeYKeNBS5WTRos5nMGWyd6tFqb1f6I4vZz1jFnFIJsoLLZ_-f1y66PZyMD_XhwdHoObrDwmmKdTZ30Ha9XPsXoBPW5ct4EDH6ft0n_y8a-HsJ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intensified+conditioning+containing+decitabine+versus+standard+myeloablative+conditioning+for+adult+patients+with+KMT2A-rearranged+leukemia%3A+a+multicenter+retrospective+study&rft.jtitle=BMC+medicine&rft.au=Hu%2C+Zhongli&rft.au=Feng%2C+Zinan&rft.au=Liu%2C+Shiqi&rft.au=He%2C+Hai&rft.date=2024-12-31&rft.issn=1741-7015&rft.eissn=1741-7015&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12916-024-03830-0&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12916_024_03830_0 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |